Daclatasvir, Sofosbuvir

Daclatasvir and Sofosbuvir is a combination medication used for the treatment of chronic hepatitis C virus (HCV) infection. This medication is specifically designed to target and suppress the HCV, helping to clear the virus from the body and reduce the risk of liver damage.
Daclatasvir is an NS5A inhibitor, which works by blocking the replication of the HCV virus within the liver cells. Sofosbuvir, on the other hand, is a nucleotide analogue NS5B polymerase inhibitor, which prevents the virus from replicating by interfering with its ability to produce new viral particles.
The combination of Daclatasvir and Sofosbuvir is highly effective in treating a wide range of HCV genotypes, making it a popular choice for patients with chronic HCV infection. This medication is typically prescribed for 12 weeks, depending on the severity of the infection and the patient’s individual needs.
Daclatasvir and Sofosbuvir should only be used under the supervision of a healthcare professional, as it may cause side effects in some individuals. Common side effects include fatigue, headache, and nausea. Patients should inform their healthcare provider if they experience any severe or persistent side effects while taking this medication.